SCHEMBL6073595

SCHEMBL6073595

COc1ccc2c(n1)CC(=O)N2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 2/20 0.44
PDE3A Q14432 2/20 0.44
OPRL1 P41146 1/20 0.40
NPC1 O15118 2/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
RAB9A P51151 2/20 0.39
KMT2A Q03164 2/20 0.39
HSP90AA1 P07900 1/20 0.39
DDB1 Q16531 2/20 0.38
CRBN Q96SW2 2/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
BTK Q06187 1/20 0.36
ALDH1A1 P00352 1/20 0.36
AHR P35869 2/20 0.35
PDK2 Q15119 1/20 0.35
BRD4 O60885 1/20 0.34
CREBBP Q92793 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073418 0.85 CRBN (0.43) PDE3BPDE3ANPC1MEN1MAPT
SCHEMBL20095521 0.82 CRBN (0.42) PDE3BPDE3AOPRL1NPC1MEN1
SCHEMBL5621795 0.81 MAPT (0.36) PDE3BPDE3AOPRL1NPC1MEN1
SCHEMBL15806897 0.77 CYP2C19 (0.42) PDE3BPDE3ANPC1MAPTRAB9A
SCHEMBL477772 0.77 AHR (0.42) PDE3BPDE3AMAPTALDH1A1AHR
SCHEMBL4314874 0.73 XIAP (0.47) PDE3BPDE3AOPRL1NPC1MEN1
SCHEMBL1428730 0.73 DDB1 (0.37) OPRL1NPC1MEN1MAPTRAB9A
SCHEMBL24192469 0.73 AHR (0.38) PDE3BPDE3AMAOAMAOBALDH1A1
SCHEMBL21874251 0.73 AHR (0.38) PDE3BPDE3AMAPTALDH1A1AHR
SCHEMBL29930637 0.73 AHR (0.46) PDE3BPDE3ANPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3414247-B1 SPIROINDOLINONES AS DDR1 INHIBITORS HOFFMANN LA ROCHE (CH) 2021-04-21 EP disclosed
US-10618897-B2 Spiroindolinones as DDR1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-04-14 US disclosed
US-20190071444-A1 SPIROINDOLINONES AS DDR1 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-03-07 US disclosed
EP-3414247-A1 SPIROINDOLINONES AS DDR1 INHIBITORS H. Hoffnabb-La Roche Ag (CH) 2018-12-19 EP disclosed
WO-2017137334-A1 SPIROINDOLINONES AS DDR1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2017-08-17 WO disclosed
US-7119207-B2 Benzoamide piperidine containing compounds and related compounds PFIZER INC (US) 2006-10-10 US disclosed
EP-1272484-B1 BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS PFIZER PROD INC (US) 2005-07-20 EP disclosed
US-20030087925-A1 Benzoamide piperidine containing compounds and related compounds PFIZER INC. 2003-05-08 US disclosed
EP-1272484-A2 BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS Pfizer Products Inc. (US) 2003-01-08 EP disclosed
WO-2001077100-A2 BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS PFIZER PRODUCTS INC. (US) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10618897-B2 Spiroindolinones as DDR1 inhibitors DDR1, DDR2, DDRGK1 PDE3B 2321/4885PDE3A 1818/4885OPRL1 3346/4885
US-20190071444-A1 SPIROINDOLINONES AS DDR1 INHIBITORS DDR1, DDR2, DDRGK1 PDE3B 2321/4885PDE3A 1818/4885OPRL1 3346/4885
US-20030087925-A1 Benzoamide piperidine containing compounds and related compounds TACR1, VIPR1, VIPR2 PDE3B 624/4885PDE3A 362/4885OPRL1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.